Epicast Report: Diabetic Macular Edema – Epidemiology Forecast to 2023: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with Epicast Report: Diabetic Macular Edema – Epidemiology Forecast to 2023 in subject line and your contact details. Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell (edema). The swelling may distort a person's central vision, as the macula is near the center of the retina at the back of the eyeball. This area holds tightly packed cones that provide sharp, clear central vision to enable a person to see detail, form, and color that is directly in the direction of gaze. Macular edema (ME) occurs due to the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. In ME, fluid and protein deposits collect on or under the macula of the eye, due to a breakdown in the blood-retinal barrier. The occurrence of ME is highly frequent in diabetics and usually manifests itself as diabetic macular edema (DME). DME is often a complication of diabetic retinopathy, and is the most common cause of vision loss in individuals with diabetes, especially if left untreated. The risk for ME is high in patients with retinal vein occlusion (RVO), which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). GlobalData epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population in the 7MM will increase by 34.2% during the forecast period, from 922,492 cases in 2013 to 1,238,301 cases in 2023. The total prevalent cases of ME following BRVO in the 7MM will increase by 13.7% during the forecast period, from 294,862 cases in 2013 to 335,346 cases in 2023. The total prevalent cases of ME following CRVO in the 7MM will increase by 19.6% during the forecast period, from 114,571 cases in 2013 to 136,973 cases in 2023. GlobalData’s epidemiological analysis is supported by the use of country-specific prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population and the total prevalent cases of ME following BRVO and CRVO, to allow for a meaningful comparison of the disease populations across markets.
Complete report available at http://www.marketoptimizer.org/epicast-report-diabetic-macularedema-epidemiology-forecast-to-2023.html . Scope The Diabetic Macular Edema (DME) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for DME in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population and the total prevalent cases of ME following branch retinal vein occlusion (BRVO) and central retinal vein occlusion
(CRVO) segmented by sex and age (20–39 years, 40–59 years, 60–79 years, and =80 years) in these markets. The DME epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Inquire for discount @ http://www.marketoptimizer.org/contacts/discount?rname=10264 (Report price: Single user license- US$ 3995 ) Reasons to Buy Develop business strategies by understanding the trends shaping and driving the global DME market. Quantify patient populations in the global DME market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for DME therapeutics in each of the markets covered. Identify the number of ME cases following BRVO and CRVO.
Buy a Copy of Report @ http://www.marketoptimizer.org/contacts/purchase?rname=10264 . Table of Contents For This Report Table of Contents 1 Table of Contents 1 1.1 List of Tables 3 1.2 List of Figures 4 2 Executive Summary 4 3 Introduction 7 3.1 Catalyst 7 3.2 Related Reports 8 3.3 Upcoming Reports 8 4 Epidemiology 8 4.1 Disease Background 8
4.2 Risk Factors and Comorbidities 9
Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “Epicast Report: Diabetic Macular Edema – Epidemiology Forecast to 2023” report OR for any other market research and intelligence needs you may have for your business.